Davide Campari-Milano N.V. (CPR) Fair Value & Analysis
Consumer Defensive · IT · Market cap €7.2B · ISIN NL0015435975
What is Davide Campari-Milano N.V. really worth?
A solid business, but trading 45% above our fair value of €3.98.
Strengths
Risks
For context
Fair value as of: Sep 1, 2026
From 24 valuation models · updated 4 days ago
Share price −1.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (€2.63 to €6.14) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 1, 2026.
How to read this chart
60‑month range €5.01 – €12.88 · fair‑value band €2.63 – €6.14 · the €5.77 price screens above the €3.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 1, 2026.
Analysis
Davide Campari-Milano N.V. (CPR) currently trades at €5.77, while our model-based Fair Value estimate is €3.98, implying the stock looks roughly 45.0% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector. Bull case: the Growth Earnings group reads highest at a median of €5.32 per share, and 5 of the 24 models we run sit above the €5.77 price. Bear case: the Earnings-Based group reads lowest at €1.81, and 19 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Davide Campari-Milano N.V. generated revenue of €3.1B at a net margin of 11.4%. Revenue declined 2.8% year over year. It earns a return on equity of 8.6%. Net debt stands at €1.8B. Fundamentals as of Sep 1, 2026
Our scenario range runs from €2.63 (bear case) to €6.14 (bull case); at €5.77, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at −4% fair-value upside, at −31%, CPR screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly €0.1286 per share, which is 3.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings (€5.32) versus Earnings-Based (€1.81). Highest evidence: FCF DCF (78).
Notify me when CPR reaches fair value
Put CPR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Davide Campari-Milano N.V., together with its subsidiaries, trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
Full company description
Davide Campari-Milano N.V., together with its subsidiaries, trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers a range of products, including aperitifs, vodka, whisky, rum, agave, cognac, and champagne under the Aperol, Campari, Picon, Cynar, Sarti Rosa, Campari Soda, Crodino, Aperol Spritz RTE, Wild Turkey, Appleton Estate, Wray and Nephew, The GlenGrant, Wilderness Trail, Espolòn, Ancho Reyes, Montelobos, Grand Marnier, Courvoisier, Bisquit, Champagne Lallier, SKYY Vodka, Bulldog Gin, Averna, Braulio, Forty Creek, Frangelico, Cabo Wabo, Del Professore, Mondoro, Riccadonna, La Mauny, Trois Rivieres, Kingston 62, O'ndina, Bickens, Dreher, Ouzo 12, Sagabita, and Zedda Piras brand names. Davide Campari-Milano N.V. was founded in 1860 and is headquartered in Sesto San Giovanni, Italy. Davide Campari-Milano N.V. operates as a subsidiary of Lagfin S.C.A.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Davide Campari-Milano N.V. reported revenue of €3.1B in FY2025 versus €2.2B in FY2021, a compound +8.9%/yr. Reported net income was €346M in FY2025, compounding +5.0%/yr from FY2021.
of which total revenue +7.0 % · buybacks/dilution +0.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
CPR screens 45% overvalued. Compare with Kweichow Moutai Co →
Peer Group
Beverages - Wineries & Distilleries · 94 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Beverages - Wineries & Distilleries median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Beverages - Wineries & Distilleries stocks, each showing price versus our Fair Value estimate (as of Sep 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Kweichow Moutai Co 600519 | ¥1,303 | ¥1,238 | −5% |
| Diageo plc DEO | $92.99 | $73.29 | −21% |
| Wuliangye Yibin Co 000858 | ¥71.89 | ¥48.44 | −33% |
| Shanxi Xinghuacun Fen Wine Factory Co 600809 | ¥116.39 | ¥185.80 | +60% |
| Pernod Ricard SA RI | €63.20 | €76.13 | +20% |
| Luzhou Laojiao Co 000568 | ¥84.50 | ¥149.17 | +77% |
| Brown-Forman Corporation BFA | $28.72 | $27.69 | −4% |
| United Spirits Limited UNITDSPR | ₹1,528 | ₹285.39 | −81% |
| Thai Beverage Public Company Y92 | 0.4650 SGD | 0.7000 SGD | +51% |
| Jiangsu Yanghe Distillery Co 002304 | ¥39.59 | ¥27.82 | −30% |
Compare Davide Campari-Milano N.V. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Davide Campari-Milano N.V. (CPR) overvalued or undervalued?
What is the fair value of CPR?
What is the quality score of CPR?
What is the revenue of Davide Campari-Milano N.V. (CPR)?
What is the net profit margin of CPR?
Does Davide Campari-Milano N.V. pay a dividend?
Watch Davide Campari-Milano N.V. in the live analysis
One click puts Davide Campari-Milano N.V. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.